Effect of recombinant growth hormone on leptin, adiponectin, resistin, interleukin-6, tumor necrosis factor-α and ghrelin levels in growth hormone-deficient children
Tóm tắt
Background: Treatment with GH promotes linear growth and decreases body fat in patients with isolated GH deficiency (GHD). However, few studies have analyzed how GH replacement modifies ghrelin levels and the adipokine profile and the relationship of these modifications with the metabolic changes. Aims: To analyze the eventual differences between serum levels of leptin, leptin soluble receptor (sOBR), resistin, adiponectin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), otal (TG) and acylated ghrelin (AG) and lipid and glycemic profiles in children with GHD, as well as to determine the effect of GH replacement on these parameters during the first year of therapy. Subjects and methods: Thirty pre-pubertal (Tanner stage I) GHD children and 30 matched controls were enrolled. Children with GHD were studied before and after 6 and 12 months of GH treatment. Weight, height, BMI, fasting glucose, insulin, lipid profile and serum levels of adipokines and ghrelin were studied at every visit. Adipokines, insulin and ghrelin levels were determined by using commercial radio- and enzymoimmunoassays. Results: At baseline children with GHD had significantly higher sO-BR (p<0.01) and adiponectin (p<0.01) levels than controls. Treatment with GH resulted in a decline in leptin (p<0.05) and TG (p<0.001) levels, an increase of homeostasis model assessment index and restored IGF-I levels (p<0.001). Conclusions: These data indicate that GH replacement has a negative effect on leptin levels and may also produce a slight unfavorable effect on carbohydrate metabolism. In addition, the changes observed in the adipokine profile appear to be independent of body mass index.
Tài liệu tham khảo
van der Sluis IM, Boot AM, Hop WC, De Rijke YB, Krenning EP, de Muinck Keizer-Schrama SM. Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficient children: a 6-year follow-up study. Horm Res 2002, 58: 207–14.
Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89: 2548–56.
Yu WH, Kimura M, Walczewska A, Karanth S, McCann SM. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci USA 1997, 94: 1023–8.
Kratzsch J, Lammert A, Bottner A, et al. Circulating soluble leptin receptor and free leptin index during childhood, puberty, and adolescence. J Clin Endocrinol Metab 2002, 87: 4587–94.
Carraro R, Portillo MP, Garaulet M, Martínez JA, Obregón JM. Investigación básica en obesidad. Rev Esp Obes 2003, 1: 71–6.
Frübeck G, Gómez-Ambrosi J, Muruzábal FJ, Burrel MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol 2001, 280: 827–47.
Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008, 93 (Suppl 1): S64–73.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402: 656–60.
Del Rincón JP, Iida K, Gaylinn BD, et al. Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 2007, 56: 1638–46.
Hernández M, Castellet J, Narvaíz J, et al. Curvas y Tablas de Crecimiento. 3rd ed. Bilbao: Fundación F. Orbegozo, 2002.
Moreno LA, Fleta J, Mur L, Rodríguez G, Sarría A, Bueno M. Waist circumference values in Spanish children-gender related differences. Eur J Clin Nutr 1999, 53: 429–33.
Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd edition. Stanford University Press, Stanford 1959.
Bayley N, Pinneau S. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J. Pediatr 1952, 14: 423–41.
Barrios V, Pozo J, Muñoz MT, Buño M, Argente J. Normative data for total and free acid-labile subunit of the human insulin-like growth factor-binding protein complex in pre- and full-term new-borns and healthy boys and girls throughout postnatal development. Horm Res 2000, 53: 148–53.
Ciresi A, Amato MC, Criscimanna A, et al. Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol 2007, 156: 353–60.
Joaquin C, Aguilera E, Granada ML, et al. Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur J Endocrinol 2008, 158: 483–90.
Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T. Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 1998, 83: 3476–9.
Giavoli C, Cappiello V, Corbetta S, et al. Different effects of short-and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults. Clin Endocrinol (Oxf) 2004, 61: 81–7.
Festen DA, van Toorenenbergen A, Duivenvoorden HJ, Hokken-Koelega AC. Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy. J Clin Endocrinol Metab 2007, 92: 1549–54.
Angulo M, Castro-Magana M, Mazur B, Canas JA, Vitollo PM, Sarrantonio M. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab 1996, 9: 393–400.
Bray GA, Dahms WT, Swerdloff RS, Fiser RH, Atkinson RL, Carrel RE. The Prader-Willi syndrome: a study of 40 patients and a review of the literature. Medicine (Baltimore) 1983, 62: 59–80.
Lanes R, Soros A, Gunczler P, et al. Growth hormone deficiency, low levels of adiponectin, and unfavorable plasma lipid and lipoproteins. J Pediatr 2006, 149: 324–9.
Herrmann BL, Saller B, Stratmann M, Berg C, Mann K, Janssen OE. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome. Horm Metab Res 2005, 37: 49–52.
Andersson B, Carlsson LM, Carlsson B, Albertsson-Wikland K, Bjarnason R; Swedish Study Group for Growth Hormone Treatment. Decrease in adiponectin levels correlates to growth response in growth hormone-treated children. Horm Res 2009, 71: 213–8.
Edén Engström B, Burman P, Holdstock C, Karlsson FA. Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J Clin Endocrinol Metab 2003, 88: 5193–8.
van Dielen FM, van ’t Veer C, Buurman WA, Greve JW. Leptin and soluble leptin receptor levels in obese and weight-losing individuals. J Clin Endocrinol Metab 2002, 87: 1708–16.
Kriström B, Carlsson B, Rosberg S, Carlsson LM, Albertsson-Wikland K. Short-term changes in serum leptin levels provide a strong metabolic marker for the growth response to growth hormone treatment in children. Swedish Study Group for Growth Hormone Treatment. J Clin Endocrinol Metab 1998, 83: 2735–41.
Tillmann V, Patel L, Gill MS, et al. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Clin Endocrinol (Oxf) 2000, 53: 329–36.
Matsuoka H, Fors H, Bosaeus I, Rosberg S, Albertsson-Wikland K, Bjarnason R. Changes in body composition and leptin levels during growth hormone (GH) treatment in short children with various GH secretory capacities. Eur J Endocrinol 1999, 140: 35–42.
Elimam A, Norgren S, Marcus C. Effects of growth hormone treatment on the leptin system and body composition in obese prepubertal boys. Acta Paediatr 2001, 90: 520–5.
Edén Engström B, Burman P, Holdstock C, Karlsson FA. Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J Clin Endocrinol Metab 2003, 88: 5193–8.
Nyström F, Ekman B, Osterlund M, Lindström T, Ohman KP, Arnqvist HJ. Serum leptin concentrations in a normal population and in GH deficiency: negative correlation with testosterone in men and effects of GH treatment. Clin Endocrinol (Oxf) 1997, 47: 191–8.
Florkowski CM, Collier GR, Zimmet PZ, Livesey JH, Espiner EA, Donald RA. Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 1996; 45: 769–73.
Guerre-Millo M. Adiponectin: an update. Diabetes Metab 2008, 34: 12–8.
Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ, et al. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin Endocrinol (Oxf) 2004, 60: 442–50.
Ridderstråle M. Signaling mechanism for the insulin-like effects of growth hormone—another example of a classical hormonal negative feedback loop. Curr Drug Targets Immune Endocr Metabol Disord 2005, 5: 79–92.
Nozue H, Kamoda T, Matsui A. Serum resistin concentrations in growth hormone-deficient children during growth hormone replacement therapy. Metabolism 2007, 56: 1514–7.
Jung CH, Lee WY, Rhee EJ, Kim SY, Oh KW, Yun EJ, Kim SW. Serum ghrelin and leptin levels in adult growth hormone deficiency syndrome. Arch Med Res 2006, 37: 612–8.
Hauffa BP, Haase K, Range IM, Unger N, Mann K, Petersenn S. The effect of growth hormone on the response of total and acylated ghrelin to a standardized oral glucose load and insulin resistance in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2007, 92: 834–40.
De Vriese C, Gregoire F, Lema-Kisoka R, Waelbroeck M, Robberecht P, Delporte C 2004 Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. Endocrinology 2004, 145: 4997–5005.
Salomon F, Cuneo RC, Hesp R, Sönksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989, 321: 1797–803.
Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50: 707–9.
Saad MF, Bernaba B, Hwu CM, et al. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 2002, 87: 3997–4000.
Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001, 86: 5083–6.
Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004, 53: 152–8.
Andiran N, Yordam N. TNF-alpha levels in children with growth hormone deficiency and the effect of long-term growth hormone replacement therapy. Growth Horm IGF Res 2007, 17: 149–53.
Pagani S, Meazza C, Travaglino P, De Benedetti F, Tinelli C, Bozzola M. Serum cytokine levels in GH-deficient children during substitutive GH therapy. Eur J Endocrinol 2005, 152: 207–10.
Argente J, Barrios V, Pozo J, et al. Normative data for insulin-like growth factors (IGFs), IGF-binding proteins, and growth hormone-binding protein in a healthy Spanish pediatric population: age- and sex-related changes. J Clin Endocrinol Metab 1993, 77: 1522–8.